Hefei Lifeon Pharmaceutical Co., Ltd.
立方制药
003020
Shenzhen Stock Exchange
Company Profile
The company's highlights lie in its leading advantage in the field of osmotic pump technology within the domestic pharmaceutical industry. It has consistently focused on research and development in various aspects of osmotic pump technology, including formulation, formulation evaluation, formulation engineering, and critical equipment technology. Through technical research and development on crucial elements of osmotic pump formulations, the company has achieved technological breakthroughs, mastered various critical osmotic pump technologies, and gradually established the osmotic pump technology platform. By leveraging this technical advantage, the company has gained a competitive edge in the market and steadily proved its core competitiveness of sustained/controlled release preparation industrialization. The core technology, "Research and Industrial Application of Osmotic Pump Controlled-Release Technology for Poorly Soluble Drugs with Single-Layer Core," was awarded the first prize in the 2018 Anhui Science and Technology Awards. The company has continuously enhanced its capabilities in sustained/controlled-release formulation development and industrialization, strengthened the production and profitability of existing sustained/controlled-release products and built a rich pipeline of sustained/controlled-release products. Currently, the company has launched several sustained/controlled-release products in the market, including Felodipine Extended-Release Tablets, Doxazosin Mesylate Extended-release Tablets, Nifedipine Controlled-Release Tablets, Trimetazidine Hydrochloride Modified-release Tablets, Venlafaxine Hydrochloride Sustained-Release Tablets and Oxycodone Hydrochloride Prolonged -Release Tablets. Additionally, several sustained/controlled release formulations are in various stages of development, such as bioequivalence studies, pilot-scale production, and pharmaceutical research. The company is actively expanding its presence in the central nervous system drugs market, which includes medications for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases that affect the central nervous system. The company has obtained designated production licenses for anaesthetic drugs(Oxycodone Hydrochloride Prolonged-Release Tablets). Both Venlafaxine Hydrochloride Extended-Release Tablets and Oxycodone Hydrochloride Prolonged-Release Tablets have been approved for marketing. Large-size (40mg) Oxycodone Hydrochloride Prolonged-Release Tablets have been registered. Methylphenidate Hydrochloride Sustained-Release Tablets are bioequivalence studies, and several other central nervous system drugs are currently in the research and development stage. This strategic move aims to create new core competencies for the company. The company also offers a range of distinctive products, including Yiqi Hewei Capsules, Kunning Granules, Armillariella Oral Solution, Paeonol Ointment, Kecuoyintong Gel, and Jinzhen Eye Drops, covering various fields such as digestion, dermatology, gynaecology, and ophthalmology. The ophthalmology and dermatology products have pharmaceutical and consumer attributes, showing strong market potential and performing well at the retail level. Additionally, the company has independently developed and produced some active pharmaceutical ingredients, excipients, and pharmaceutical intermediates. The formulation products like Felodipine Extended-Release Tablets, Urea Vitamin E Cream, Paeonol Ointment, and Doxazosin Mesylate Extended-Release Tablets enable the company to achieve self-sufficiency in critical raw materials and excipients, ensuring cost advantages during centralized procurement.
Full description
Founded in 2002, Hefei Lifeon Pharmaceutical Co., Ltd. (Stock Code: 003020) focuses on the pharmaceutical industry and pharmaceutical commerce. In the pharmaceutical industry, the company focuses on the R&D, production, and sales of pharmaceutical products and active pharmaceutical ingredients. The product pipelines include cardiovascular, gastrointestinal, dermatological, ophthalmology and CNS products. The company consists of the wholesale distribution and retailing of pharmaceutical and medical devices. In 2023, the company partially divested assets related to the pharmaceutical wholesale distribution business, China Resources Glory Health Technology (Beijing) Co., Ltd(China Resources Glory) acquired the control (51% equity) of the company's subsidiary Anhui Lifeon Pharmaceuticals in the form of capital increase. 1. Pharmaceutical Industry The company focuses on the sustained/controlled release preparation technology represented by osmotic pump controlled-release technology. It has developed an osmotic pump controlled-release technology platform comprising four key components: formulation, formulation evaluation, formulation engineering, and critical equipment technology. The company continuously enhances its capabilities in developing and industrializing osmotic pump formulations. This technology platform has created the company's advantage in industrializing sustained/controlled release preparation technology. Its main products include Felodipine Extended-Release Tablets, Doxazosin Mesylate Extended-release Tablets, Nifedipine Controlled-Release Tablets, Trimetazidine hydrochloride Modified Release Tablets, Venlafaxine Hydrochloride Sustained-Release Tablets, and Oxycodone Hydrochloride Prolonged-Release Tablets. The company possesses exclusive pharmaceutical products such as Yiqi Hewei Capsules, Kunning Granules, Paeonol Ointment, Kecuoyintong Gel, Jinzhen Eye Drops, and other active pharmaceutical ingredients(APIs). The Oxycodone Hydrochloride Prolonged-Release Tablets was approved on March 2023, the company's first anaesthetic drug, becoming the first domestic generic listed enterprise with a 10mg specification of this product. In the chemical APIs field, production approvals have been granted for Felodipine, Doxazosin Mesylate, Paeonol, and Urea, ensuring self-sufficiency in the supply of significant preparation products. The company has established a sulfhydryl technology platform. In July 2018, the company passed the FDA's (U.S. Food and Drug Administration) on-site inspection for its Dimercaptosuccinic Acid production facility without any defects in the facilities and standards. 2. Pharmaceutical Commerce The company has established a modern logistics distribution centre and actively expanded its upstream and downstream cooperative networks. It has developed strong distribution service capabilities and a specific advantage in wholesale pharmaceutical distribution within Anhui Province. In 2023, the company partially divested assets related to the pharmaceutical wholesale distribution business. China Resources Glory acquired control of the company's subsidiary, Anhui Lifeon Pharmaceutical Co., Ltd, through a capital increase. On April 28, 2023, Anhui Lifeon Pharmaceutical Co., Ltd. completed capital increase, renaming, shareholder changes, and other business registration procedures. The company's name was changed to "China Resources Lifeon Pharmaceutical (Anhui) Co., Ltd." After completing the capital increase business registration, China Resources Glory holds 51% of the equity of Anhui Lifeon Pharmaceuticals. The company owns 49% of the equity. The company's consolidated financial statements will no longer include the commerce sector. This transaction will reduce the company's asset-liability ratio, optimize the asset structure, and facilitate its focus on the pharmaceutical industry, enhancing its competitiveness in pharmaceutical commerce. The company's wholly-owned subsidiary, Lifeon Chain Pharmacies, operates over 60 retail chain pharmacies in Hefei City and surrounding areas, actively expanding its pharmaceutical retail business at the terminal level.